hydroxyurea has been researched along with Meningeal Neoplasms in 27 studies
Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas." | 9.22 | Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S, 2016) |
| "We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma." | 9.16 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012) |
| "Hydroxyurea treatment is of marginal efficacy for meningioma and must not be considered as an alternative if radiotherapy or surgery is feasible." | 9.11 | [Hydroxyurea treatment for unresectable meningioma]. ( Barrie-Attarian, M; Chinot, O; Dufour, H; Fuentes, S; Grisoli, F; Métellus, P; Paz-Paredes, A, 2004) |
| "Hydroxyurea was administered at a dosage of approximately 20 mg/kg/day to 11 women and nine men (median age 59 years, range 31-75 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple)." | 9.10 | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002) |
| "In this paper the authors present the first evidence that meningiomas respond to treatment with hydroxyurea." | 9.08 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
| "Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard chemotherapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature." | 7.78 | Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. ( Chamberlain, MC, 2012) |
| "Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature." | 7.77 | Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. ( Chamberlain, MC; Johnston, SK, 2011) |
| "Although the chemotherapy drug hydroxyurea (HU) and the antiprogesterone mifepristone (RU486) have been used to treat meningiomas for which surgical and radiation therapies have failed, results have been disappointing." | 7.73 | Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro. ( Gillespie, DL; Jensen, RL; Kelly, D; Kushnir, V; Polevaya, N; Ragel, BT, 2006) |
| "We report the case of a 65-year-old woman who developed symptoms of spinal cord compression due to a spinal meningioma after 10 years of treatment with hydroxyurea (1000 mg/day) for essential thrombocytemia." | 7.71 | Spinal meningioma during hydroxyurea therapy. A paradoxycal case report. ( Giordano, F; Pagni, CA; Savarino, A, 2002) |
| "Meningiomas are slow growing, extraaxial tumors that derive from the arachnoidal cap cells of the meninges." | 6.44 | Hydroxyurea chemotherapy in the treatment of meningiomas. ( Newton, HB, 2007) |
| "4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg." | 6.43 | Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005) |
| "High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival." | 5.62 | Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients. ( Basuli, F; Berry, MR; Botham, RC; Chen, Z; Daniel, GB; Fan, TM; Hergenrother, PJ; Huang, S; Joslyn, SK; LeBlanc, AK; Rao, J; Riggins, GJ; Rossmeisl, JH; Tonogai, EJ; Zhang, X, 2021) |
| "Hydroxyurea has modest activity against meningiomas and should be considered for patients who are poor surgical candidates, have unresectable or large residual meningiomas, or have progressed after surgical resection or irradiation, or both." | 5.32 | Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. ( Newton, HB; Scott, SR; Volpi, C, 2004) |
| "Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes." | 5.31 | Treatment of high risk or recurrent meningiomas with hydroxyurea. ( Ashley, DL; Cher, L; Rosenthal, MA, 2002) |
| "Hydroxyurea is an agent that inhibits ribonucleotide reductase and can induce apoptosis in meningioma cell cultures and animal models." | 5.31 | Hydroxyurea chemotherapy for unresectable or residual meningioma. ( Newton, HB; Slivka, MA; Stevens, C, 2000) |
| "Short-term treatment of meningioma cell cultures with hydroxyurea for 24 to 48 hours resulted in discrete oligonucleosomal fragments (DNA ladder), another characteristic sign of apoptosis." | 5.30 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
| "Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas." | 5.22 | Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S, 2016) |
| "We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma." | 5.16 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012) |
| "Hydroxyurea treatment is of marginal efficacy for meningioma and must not be considered as an alternative if radiotherapy or surgery is feasible." | 5.11 | [Hydroxyurea treatment for unresectable meningioma]. ( Barrie-Attarian, M; Chinot, O; Dufour, H; Fuentes, S; Grisoli, F; Métellus, P; Paz-Paredes, A, 2004) |
| "Hydroxyurea was administered at a dosage of approximately 20 mg/kg/day to 11 women and nine men (median age 59 years, range 31-75 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple)." | 5.10 | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002) |
| "In this paper the authors present the first evidence that meningiomas respond to treatment with hydroxyurea." | 5.08 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
| "Current guidelines recommend only 3 drugs that can be used to treat patients with refractory and highgrade meningiomas: hydroxyurea, interferon-α 2B, and Sandostatin long-acting release." | 4.89 | Recent developments in chemotherapy for meningiomas: a review. ( Moazzam, AA; Wagle, N; Zada, G, 2013) |
| "Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard chemotherapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature." | 3.78 | Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. ( Chamberlain, MC, 2012) |
| "Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature." | 3.77 | Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. ( Chamberlain, MC; Johnston, SK, 2011) |
| "Although the chemotherapy drug hydroxyurea (HU) and the antiprogesterone mifepristone (RU486) have been used to treat meningiomas for which surgical and radiation therapies have failed, results have been disappointing." | 3.73 | Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro. ( Gillespie, DL; Jensen, RL; Kelly, D; Kushnir, V; Polevaya, N; Ragel, BT, 2006) |
| "We report the case of a 65-year-old woman who developed symptoms of spinal cord compression due to a spinal meningioma after 10 years of treatment with hydroxyurea (1000 mg/day) for essential thrombocytemia." | 3.71 | Spinal meningioma during hydroxyurea therapy. A paradoxycal case report. ( Giordano, F; Pagni, CA; Savarino, A, 2002) |
| "Meningiomas are benign tumors of the central nervous system, with low recurrence risk for World Health Organization (WHO) grade I lesions but a high risk for WHO grade II and III lesions." | 2.53 | Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. ( Cohen, A; Colman, H; Guan, J; Jensen, RL; Karsy, M, 2016) |
| "Meningiomas are slow growing, extraaxial tumors that derive from the arachnoidal cap cells of the meninges." | 2.44 | Hydroxyurea chemotherapy in the treatment of meningiomas. ( Newton, HB, 2007) |
| "4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg." | 2.43 | Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005) |
| "High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival." | 1.62 | Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients. ( Basuli, F; Berry, MR; Botham, RC; Chen, Z; Daniel, GB; Fan, TM; Hergenrother, PJ; Huang, S; Joslyn, SK; LeBlanc, AK; Rao, J; Riggins, GJ; Rossmeisl, JH; Tonogai, EJ; Zhang, X, 2021) |
| "We report a case with malignant meningioma in which new preliminary treatment trial was performed by chemotherapy using anti-cancer drugs selected on the basis of multidrug resistance gene mRNA expression, such as MDR1, MGMT, MRP1, MRP2, MXR1, and DNA topoisomerase II alpha, from RT-PCR assay." | 1.34 | [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene]. ( Kagawa, M; Kobayashi, K; Kunishio, K; Makabe, T; Matsumoto, A; Matsumoto, Y, 2007) |
| "Hydroxyurea has modest activity against meningiomas and should be considered for patients who are poor surgical candidates, have unresectable or large residual meningiomas, or have progressed after surgical resection or irradiation, or both." | 1.32 | Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. ( Newton, HB; Scott, SR; Volpi, C, 2004) |
| "Hydroxyurea is an agent that inhibits ribonucleotide reductase and can induce apoptosis in meningioma cell cultures and animal models." | 1.31 | Hydroxyurea chemotherapy for unresectable or residual meningioma. ( Newton, HB; Slivka, MA; Stevens, C, 2000) |
| "Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes." | 1.31 | Treatment of high risk or recurrent meningiomas with hydroxyurea. ( Ashley, DL; Cher, L; Rosenthal, MA, 2002) |
| "Short-term treatment of meningioma cell cultures with hydroxyurea for 24 to 48 hours resulted in discrete oligonucleosomal fragments (DNA ladder), another characteristic sign of apoptosis." | 1.30 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Tonogai, EJ | 1 |
| Huang, S | 1 |
| Botham, RC | 1 |
| Berry, MR | 1 |
| Joslyn, SK | 1 |
| Daniel, GB | 1 |
| Chen, Z | 1 |
| Rao, J | 1 |
| Zhang, X | 1 |
| Basuli, F | 1 |
| Rossmeisl, JH | 1 |
| Riggins, GJ | 1 |
| LeBlanc, AK | 1 |
| Fan, TM | 1 |
| Hergenrother, PJ | 1 |
| Abdel Karim, K | 1 |
| El Shehaby, A | 1 |
| Emad, R | 1 |
| Reda, W | 1 |
| El Mahdy, M | 1 |
| Ghali, R | 1 |
| Nabeel, A | 1 |
| Moazzam, AA | 1 |
| Wagle, N | 1 |
| Zada, G | 1 |
| Wilisch-Neumann, A | 1 |
| Pachow, D | 1 |
| Wallesch, M | 1 |
| Petermann, A | 1 |
| Böhmer, FD | 1 |
| Kirches, E | 1 |
| Mawrin, C | 1 |
| Mazza, E | 1 |
| Brandes, A | 1 |
| Zanon, S | 1 |
| Eoli, M | 1 |
| Lombardi, G | 1 |
| Faedi, M | 1 |
| Franceschi, E | 1 |
| Reni, M | 1 |
| Karsy, M | 1 |
| Guan, J | 1 |
| Cohen, A | 1 |
| Colman, H | 1 |
| Jensen, RL | 2 |
| Chamberlain, MC | 2 |
| Johnston, SK | 1 |
| Reardon, DA | 1 |
| Norden, AD | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Herndon, JE | 1 |
| Coan, A | 1 |
| Sampson, JH | 1 |
| Gururangan, S | 1 |
| Peters, KB | 1 |
| McLendon, RE | 1 |
| Norfleet, JA | 1 |
| Lipp, ES | 1 |
| Drappatz, J | 1 |
| Wen, PY | 1 |
| Friedman, HS | 1 |
| Sherman, WJ | 1 |
| Raizer, JJ | 1 |
| Mason, WP | 1 |
| Gentili, F | 1 |
| Macdonald, DR | 1 |
| Hariharan, S | 1 |
| Cruz, CR | 1 |
| Abrey, LE | 1 |
| Giordano, F | 1 |
| Savarino, A | 1 |
| Pagni, CA | 1 |
| Paus, S | 1 |
| Klockgether, T | 1 |
| Urbach, H | 1 |
| Schlegel, U | 1 |
| Fuentes, S | 1 |
| Chinot, O | 1 |
| Dufour, H | 1 |
| Paz-Paredes, A | 1 |
| Métellus, P | 1 |
| Barrie-Attarian, M | 1 |
| Grisoli, F | 1 |
| Newton, HB | 3 |
| Scott, SR | 1 |
| Volpi, C | 1 |
| Hahn, BM | 1 |
| Schrell, UM | 4 |
| Sauer, R | 1 |
| Fahlbusch, R | 3 |
| Ganslandt, O | 1 |
| Grabenbauer, GG | 1 |
| Cramer, P | 1 |
| Thomale, UW | 1 |
| Okuducu, AF | 1 |
| Lemke, AJ | 1 |
| Stockhammer, F | 1 |
| Woiciechowsky, C | 1 |
| Ragel, BT | 1 |
| Gillespie, DL | 1 |
| Kushnir, V | 1 |
| Polevaya, N | 1 |
| Kelly, D | 1 |
| Kunishio, K | 1 |
| Kobayashi, K | 1 |
| Kagawa, M | 1 |
| Makabe, T | 1 |
| Matsumoto, A | 1 |
| Matsumoto, Y | 1 |
| Al-Khalaf, HH | 1 |
| Lach, B | 1 |
| Allam, A | 1 |
| Hassounah, M | 1 |
| Alkhani, A | 1 |
| Elkum, N | 1 |
| Alrokayan, SA | 1 |
| Aboussekhra, A | 1 |
| Rittig, MG | 3 |
| Koch, U | 1 |
| Marschalek, R | 3 |
| Anders, M | 3 |
| Kiesewetter, F | 2 |
| Koch, UH | 2 |
| Cusimano, MD | 1 |
| Slivka, MA | 1 |
| Stevens, C | 1 |
| Rosenthal, MA | 1 |
| Ashley, DL | 1 |
| Cher, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma[NCT00354913] | Phase 2 | 21 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time in months from the start of study treatment to date of death due to any cause. Patients alive at last follow-up are censored as of that follow-up date. Median OS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of death from any cause, assessed up to 69 months.
| Intervention | months (Median) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 66 |
Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months.
| Intervention | months (Median) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 7 |
Percentage of participants with an objective response (complete response or partial response). Per modified Macdonald criteria and assessed by MRI, complete response (CR) was the disappearance of all target lesions and partial response (PR) was a ≥50% decrease in the sum of the longest diameter of target lesions. Objective response = CR+PR. (NCT00354913)
Timeframe: 69 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 0 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or death due to any cause. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months. For each participant, PFS was assessed at 6 months after treatment initiation.
| Intervention | percentage of participants (Number) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 61.9 |
5 reviews available for hydroxyurea and Meningeal Neoplasms
| Article | Year |
|---|---|
Recent developments in chemotherapy for meningiomas: a review.
Topics: Animals; Antineoplastic Agents; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Meningeal | 2013 |
Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons.
Topics: Combined Modality Therapy; Humans; Hydroxyurea; Meningeal Neoplasms; Meningioma; Mutation; Neovascul | 2016 |
Chemotherapy: What is its role in meningioma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Education, Medical, Continuing; Evidence-Bas | 2012 |
Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progres | 2005 |
Hydroxyurea chemotherapy in the treatment of meningiomas.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Meningeal Neoplasms; Meningioma | 2007 |
5 trials available for hydroxyurea and Meningeal Neoplasms
| Article | Year |
|---|---|
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; | 2016 |
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease | 2012 |
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hydroxyurea; Karnofsky Perf | 2002 |
[Hydroxyurea treatment for unresectable meningioma].
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Meningeal Neop | 2004 |
Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Magnetic Resonance Imaging; Male; Meninge | 1997 |
17 other studies available for hydroxyurea and Meningeal Neoplasms
| Article | Year |
|---|---|
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Topics: Animals; Apoptosis; Caspase 3; Cell Culture Techniques; Cell Line, Tumor; Dogs; Humans; Hydroxyurea; | 2021 |
Role of hydroxyurea as an adjuvant treatment after Gamma knife radiosurgery for atypical (WHO grade II) meningiomas.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Hydroxyurea; Male; Meningeal Neoplasms; Meningi | 2018 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification M | 2014 |
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Drug Administrati | 2011 |
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Kaplan-Meier Est | 2012 |
Spinal meningioma during hydroxyurea therapy. A paradoxycal case report.
Topics: Aged; Antineoplastic Agents; Cervical Vertebrae; Female; Humans; Hydroxyurea; Laminectomy; Magnetic | 2002 |
Meningioma of the optic nerve sheath: treatment with hydroxyurea.
Topics: Administration, Oral; Antineoplastic Agents; Female; Humans; Hydroxyurea; Meningeal Neoplasms; Menin | 2003 |
Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Evaluation; Female; Follow-Up Studies; | 2004 |
An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
Topics: Adult; Antineoplastic Agents; Cervical Vertebrae; Decompression, Surgical; Disease Progression; Fata | 2005 |
Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cal | 2006 |
[A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B | 2007 |
Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tu | 2008 |
Hydroxyurea for treatment of unresectable meningiomas.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Magnetic Resonance Imaging; Male; Meninge | 1996 |
Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; DNA Fragmentation; Dose-Respon | 1997 |
Hydroxyurea for treatment of meningioma.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Lo | 1998 |
Hydroxyurea chemotherapy for unresectable or residual meningioma.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Female; Hemoglobins; Humans; Hydroxyurea; Leukoc | 2000 |
Treatment of high risk or recurrent meningiomas with hydroxyurea.
Topics: Adult; Aged; Antineoplastic Agents; Exanthema; Female; Humans; Hydroxyurea; Male; Meningeal Neoplasm | 2002 |